

# Scott J Antonia

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11619399/scott-j-antonia-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

81  
papers

28,350  
citations

43  
h-index

83  
g-index

83  
ext. papers

34,497  
ext. citations

11  
avg. IF

6.29  
L-index

#	Paper	IF	Citations
81	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 2443-54	59.2	8684
80	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1627-39	59.2	5964
79	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1919-1929	59.2	2034
78	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 2342-2350	59.2	1336
77	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 257-65	21.7	1050
76	Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. <i>Science</i> , <b>2002</b> , 297, 1867-70	33.3	861
75	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2004-12	2.2	859
74	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 883-895	21.7	783
73	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 31-41	21.7	605
72	Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 280-90	15.9	533
71	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , <b>2018</b> , 33, 843-852.e4	24.3	525
70	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , <b>2018</b> , 33, 853-861.e4	24.3	471
69	Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 876-83	2.2	382
68	Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 878-87	12.9	336
67	Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. <i>International Journal of Cancer</i> , <b>2002</b> , 101, 151-5	7.5	309
66	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1261-1273	21.7	266
65	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1411-1420	13.4	216

64	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 661-674	13.4	205
63	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 288-293	8.9	203
62	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4119-32	12.9	183
61	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 237-244	8.9	163
60	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , <b>2019</b> , 20, 1395-1408	21.7	149
59	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 860-867	8.9	118
58	Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 983-93	4.6	111
57	A phase I study of indoximod in patients with advanced malignancies. <i>Oncotarget</i> , <b>2016</b> , 7, 22928-38	3.3	108
56	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) <b>2018</b> , 6, 75		107
55	Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. <i>Laboratory Investigation</i> , <b>2003</b> , 83, 1457-66	5.9	104
54	Phase I Trial of a B7-1 (CD80) Gene Modified Autologous Tumor Cell Vaccine in Combination With Systemic Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , <b>2002</b> , 167, 1995-2000	2.5	98
53	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 426-435	8.9	96
52	Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 82, 924-32	4	92
51	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 974-84	8.9	86
50	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. <i>Expert Opinion on Biological Therapy</i> , <b>2010</b> , 10, 983-91	5.4	83
49	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 133, 331-338	4.8	77
48	Immuno-oncology combinations: a review of clinical experience and future prospects. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6258-68	12.9	76
47	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky021	4.6	73

46	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1670-1680	21.7	67
45	Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. <i>Cancer Biology and Therapy</i> , <b>2013</b> , 14, 860-8	4.6	63
44	Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. <i>Onc Immunology</i> , <b>2013</b> , 2, e23428	7.2	59
43	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6623-6632	12.9	59
42	Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 72-80	5	57
41	The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. <i>BMC Cancer</i> , <b>2016</b> , 16, 176	4.8	57
40	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1794-1806	8.9	47
39	A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. <i>Neoplasia</i> , <b>2017</b> , 19, 530-536	6.4	46
38	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. <i>European Journal of Cancer</i> , <b>2019</b> , 109, 154-161	7.5	42
37	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101308	2.2	42
36	A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. <i>Annals of Surgical Oncology</i> , <b>2007</b> , 14, 869-84	3.1	41
35	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3002-3002	2.2	38
34	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , <b>2018</b> , 101, 201-209	7.5	36
33	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 305-312	5.4	34
32	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , <b>2021</b> , 27, 1410-1418	50.5	31
31	Progressive hypoventilation due to mixed CD8 and CD4 lymphocytic polymyositis following tremelimumab - durvalumab treatment <b>2017</b> , 5, 54		26
30	Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. <i>Anticancer Research</i> , <b>2011</b> , 31, 3193-204	2.3	25
29	Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 35, e450-8	7.1	22

28	Durvalumab in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 869-879	9.2	21
27	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 517-527	7.4	18
26	A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. <i>Journal of Surgical Research</i> , <b>2005</b> , 125, 173-81	2.5	16
25	Immunotherapy: Beyond AntiPD-1 and AntiPD-L1 Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2016</b> , 36, e450-e458	7.1	13
24	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , <b>2018</b> , 81, 29-41	3.2	12
23	B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. <i>World Journal of Urology</i> , <b>2000</b> , 18, 157-63	4	12
22	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors <b>2021</b> , 9,		11
21	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 1853-1862	7.4	11
20	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses. <i>Cancer Medicine</i> , <b>2020</b> , 9, 225-237	4.8	9
19	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , <b>2021</b> , 151, 30-38	5.9	9
18	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 419-427	8.9	9
17	Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 109, 425-435	4	8
16	A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. <i>Breast Cancer: Targets and Therapy</i> , <b>2015</b> , 7, 389-97	3.9	7
15	Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program. <i>Patient Education and Counseling</i> , <b>2018</b> , 101, 703-710	3.1	6
14	Immunotherapy in lung cancer: "b7-bombers" and other new developments. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2013</b> , 34, 810-21	3.9	6
13	Attachment of tumor cells to endothelial monolayers: detection of surface molecules involved in cell-cell binding. <i>Clinical Immunology and Immunopathology</i> , <b>1989</b> , 53, 281-96		5
12	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 903-10	3.5	5
11	Adherence of tumor cells to endothelial monolayers: inhibition by lymphokines. <i>Cellular Immunology</i> , <b>1985</b> , 95, 247-57	4.4	4

10	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 549-561	4.9	4
9	A new role for NFB in immunosurveillance and its implications for cancer immunotherapy. <i>Onc Immunology</i> , <b>2013</b> , 2, e25963	7.2	3
8	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 3501-3510	3.1	3
7	Cell-based immune therapy for metastatic renal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2003</b> , 3, 837-49	3.5	2
6	Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS3112-TPS3112	2.2	2
5	A Bayesian pick-the-winner design in a randomized phase II clinical trial. <i>Oncotarget</i> , <b>2017</b> , 8, 88376-88385	3.5	2
4	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 1165-1184	3.6	2
3	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.. <i>Lung Cancer</i> , <b>2022</b> , 166, 84-93	5.9	0
2	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma <b>2022</b> , 10, e003956		0
1	Genetically Modified Dendritic Cell Vaccines for Solid Tumors <b>2014</b> , 273-282		